A director at Acrux Limited bought 1,455,000 shares at 0.063AUD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
We plan to cease coverage of no-moat Acrux in early November 2018 to focus on better opportunities. We provide broad coverage of more than 1,500 companies across more than 90 industry groups globally and adjust our coverage as necessary based on client demand and investor interest. Acrux is a small, high-risk, no-moat company with an uncertain future. We still think onychomycosis, and the planned launch of a generic version of branded treatment Jublia, is an attractive market for the company, gi...
We plan to cease coverage of no-moat Acrux in early November 2018 to focus on better opportunities. We provide broad coverage of more than 1,500 companies across more than 90 industry groups globally and adjust our coverage as necessary based on client demand and investor interest. Acrux is a small, high-risk, no-moat company with an uncertain future. We still think onychomycosis, and the planned launch of a generic version of branded treatment Jublia, is an attractive market for the company, gi...
We retain our AUD 0.23 per share fair value estimate for no-moat Acrux following patent litigation brought against the firm by Valeant Pharmaceuticals, subsidiary of no-moat Bausch Health Companies and owner of antifungal topical treatment Jublia. This is not surprising. In early August, the U.S. Food and Drug Administration accepted for review Acrux's Abbreviated New Drug Application dossier for its generic version of Jublia, and Acrux flagged at the announcement that the patent owner, Valeant,...
We retain our AUD 0.23 per share fair value estimate for no-moat Acrux following patent litigation brought against the firm by Valeant Pharmaceuticals, subsidiary of no-moat Bausch Health Companies and owner of antifungal topical treatment Jublia. This is not surprising. In early August, the U.S. Food and Drug Administration accepted for review Acrux's Abbreviated New Drug Application dossier for its generic version of Jublia, and Acrux flagged at the announcement that the patent owner, Valeant,...
No-moat Acrux reported full-year results in line with expectations both at the top and bottom lines marking the end of a difficult 12 months. Reported full-year loss of AUD 9 million, excluding impairments, on group revenue of AUD 2.7 million compared with our forecast loss of AUD 9 million on group revenue of AUD 2.6 million. Nonetheless, Acrux ended fiscal 2018 on a high note with AUD 28.5 million in cash on hand and 13 products in the generic pipeline. Given the recent announcement of its Abb...
Acrux is an Australian drug delivery specialist focused on developing transdermal pharmaceutical products. It uses its proprietary transdermal drug delivery technology to develop new formulations of established drugs, bringing clinical and product life cycle management benefits. Lead product Axiron was marketed in a number of countries, including the United States, by former licensee partner Eli Lilly for low testosterone levels. Other commercialised products include an estradiol spray for menop...
No-moat Acrux reported full-year results in line with expectations both at the top and bottom lines marking the end of a difficult 12 months. Reported full-year loss of AUD 9 million, excluding impairments, on group revenue of AUD 2.7 million compared with our forecast loss of AUD 9 million on group revenue of AUD 2.6 million. Nonetheless, Acrux ended fiscal 2018 on a high note with AUD 28.5 million in cash on hand and 13 products in the generic pipeline. Given the recent announcement of its Abb...
No-moat Acrux has achieved an important company milestone by confirming the U.S. Food and Drug Administration acceptance for review of its Abbreviated New Drug Application dossier for its generic version of antifungal topical solution, branded Jublia, manufactured by Valeant Pharmaceuticals. Further, the FDA confirmed the submission was made on the first possible date ahead of the data exclusivity period. Put simply, this means Acrux is well positioned to secure 180 days of generic market exclus...
No-moat Acrux has achieved an important company milestone by confirming the U.S. Food and Drug Administration acceptance for review of its Abbreviated New Drug Application dossier for its generic version of antifungal topical solution, branded Jublia, manufactured by Valeant Pharmaceuticals. Further, the FDA confirmed the submission was made on the first possible date ahead of the data exclusivity period. Put simply, this means Acrux is well positioned to secure 180 days of generic market exclus...
Acrux is an Australian drug delivery specialist focused on developing transdermal pharmaceutical products. It uses its proprietary transdermal drug delivery technology to develop new formulations of established drugs, bringing clinical and product life cycle management benefits. Lead product Axiron was marketed in a number of countries, including the United States, by former licensee partner Eli Lilly for low testosterone levels. Other commercialised products include an estradiol spray for menop...
No-moat Acrux has achieved an important company milestone by confirming the U.S. Food and Drug Administration acceptance for review of its Abbreviated New Drug Application dossier for its generic version of antifungal topical solution, branded Jublia, manufactured by Valeant Pharmaceuticals. Further, the FDA confirmed the submission was made on the first possible date ahead of the data exclusivity period. Put simply, this means Acrux is well positioned to secure 180 days of generic market exclus...
We are raising our fair value estimate for Acrux to AUD 0.15 from AUD 0.13, after incorporating forward currency assumptions for USD/AUD exchange rates and remain cautiously optimistic on the upcoming filing of the first of 12 generic product candidates for the U.S. Food and Drug Administration, or FDA, with approval expected imminently. This will represent the first generic product for the company developed in-house to reach filing stage since Axiron back almost a decade ago. Two more filings a...
We are raising our fair value estimate for Acrux to AUD 0.15 from AUD 0.13, after incorporating forward currency assumptions for USD/AUD exchange rates and remain cautiously optimistic on the upcoming filing of the first of 12 generic product candidates for the U.S. Food and Drug Administration, or FDA, with approval expected imminently. This will represent the first generic product for the company developed in-house to reach filing stage since Axiron back almost a decade ago. Two more filings a...
Acrux is an Australian drug delivery specialist focused on developing transdermal pharmaceutical products. It uses its proprietary transdermal drug delivery technology to develop new formulations of established drugs, bringing clinical and product life cycle management benefits. Lead product Axiron was marketed in a number of countries, including the United States, by former licensee partner Eli Lilly for low testosterone levels. Other commercialised products include an estradiol spray for menop...
We are raising our fair value estimate for Acrux to AUD 0.15 from AUD 0.13, after incorporating forward currency assumptions for USD/AUD exchange rates and remain cautiously optimistic on the upcoming filing of the first of 12 generic product candidates for the U.S. Food and Drug Administration, or FDA, with approval expected imminently. This will represent the first generic product for the company developed in-house to reach filing stage since Axiron back almost a decade ago. Two more filings a...
No-moat Acrux has finally reported on a difficult six-month period that culminated in the termination of its licensing agreement with Eli Lilly for lead product Axiron, the most important value driver of the stock. This followed the loss of Axiron patent protection and a flurry of generic versions entering the U.S. market. After adjusting for impairment loss of AUD 5.6 million associated with Axiron on the balance sheet, and residual legal costs attributed to the U.S. court appeal over its pat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.